Stay updated on Nivolumab Plus Ipilimumab vs. Cabazitaxel in Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab vs. Cabazitaxel in Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Plus Ipilimumab vs. Cabazitaxel in Prostate Cancer Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.4.2, replacing the previous Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-13T12:37:40.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1. No other visible content or data on the page appears to have changed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-05T16:48:54.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The page no longer displays the 'Prostate cancer' topic and the 'MedlinePlus Genetics' related topics link.
    Difference
    0.1%
    Check dated 2026-01-29T09:46:40.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Added a 'Last Update Posted' timestamp label. Removed the 'Last Update Posted (Estimated)' label, changing how update times are presented.
    Difference
    0.0%
    Check dated 2026-01-22T06:16:21.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    New page revision: v3.3.4 replaces v3.3.3. This is a minor technical update that does not affect the study details or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-15T03:21:36.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    New locations across the US, Australia, Canada, Denmark, Spain, and Poland were added. Several outcome/timeframe definitions were updated to reflect revised monitoring periods (e.g., up to approximately 93 months).
    Difference
    2%
    Check dated 2025-12-24T13:47:00.000Z thumbnail image

Stay in the know with updates to Nivolumab Plus Ipilimumab vs. Cabazitaxel in Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab vs. Cabazitaxel in Prostate Cancer Clinical Trial page.